Literature DB >> 26391641

MicroRNA-339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1.

Bo Shen1, Yan Zhang1, Shaorong Yu1, Yuan Yuan1, Yuejiao Zhong1, Jianwei Lu2, Jifeng Feng3.   

Abstract

The role of miR-339 in human gastric cancer (GC) remains unclear. Here, we found that miR-339 is remarkably decreased in primary GC tissues. Overexpression of miR-339 in GC cells significantly suppressed proliferation, migration, invasion, and tumorigenicity. Furthermore, NOVA1 was confirmed as a target of miR-339. Restoration of NOVA1 in miR-339-overexpressing GC cells partially impaired the inhibitory effects of miR-339. More importantly, epigenetic modification may be involved in the modulation of miR-339 expression. These findings uncover a novel role for miR-339 in gastric carcinogenesis, and restoration of miR-339 could be considered as a potential therapeutic strategy for GC treatment.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gastric cancer; Methylation; NOVA1; Proliferation; miR-339

Mesh:

Substances:

Year:  2015        PMID: 26391641     DOI: 10.1016/j.febslet.2015.09.009

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

1.  Identification of NOVA family proteins as novel β-catenin RNA-binding proteins that promote epithelial-mesenchymal transition.

Authors:  Shulin Tang; Yurong Zhao; Xirong He; Jiahui Zhu; Shuang Chen; Jikai Wen; Yiqun Deng
Journal:  RNA Biol       Date:  2020-03-04       Impact factor: 4.652

Review 2.  Neuro-oncological ventral antigen 1 (NOVA1): Implications in neurological diseases and cancers.

Authors:  Yu Xin; Zheng Li; Heyi Zheng; Jeffery Ho; Matthew T V Chan; William K K Wu
Journal:  Cell Prolif       Date:  2017-04-10       Impact factor: 6.831

3.  NOVA1 acts as an oncogene in osteosarcoma.

Authors:  Chengzhen Li; Ying He; Haijing Ma; Seongho Han
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

4.  LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.

Authors:  Yongxian Cao; Feng Zhang; Haotian Wang; Chunhua Bi; Jinpeng Cui; Fenghai Liu; Huazheng Pan
Journal:  Mol Cell Biochem       Date:  2020-09-23       Impact factor: 3.396

5.  NOVA1 acts as an oncogene in melanoma via regulating FOXO3a expression.

Authors:  Xin Yu; Heyi Zheng; Matthew T V Chan; William K K Wu
Journal:  J Cell Mol Med       Date:  2018-03-02       Impact factor: 5.310

6.  miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway.

Authors:  Bo Shen; Shaorong Yu; Yan Zhang; Yuan Yuan; Xiaoyou Li; Jian Zhong; Jifeng Feng
Journal:  Onco Targets Ther       Date:  2016-10-03       Impact factor: 4.147

7.  Trehalose significantly enhances the recovery of serum and serum exosomal miRNA from a paper-based matrix.

Authors:  Shu Hui Neo; Ka Yan Chung; Jia Min Quek; Heng-Phon Too
Journal:  Sci Rep       Date:  2017-11-30       Impact factor: 4.379

8.  MicroRNA-124-3p directly targets PDCD6 to inhibit metastasis in breast cancer.

Authors:  Ling Zhang; Xiangming Chen; Baoli Liu; Junqing Han
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

9.  Association between miR-124-1 rs531564 polymorphism and risk of cancer: An updated meta-analysis of case-control studies.

Authors:  Abdolkarim Moazeni-Roodi; Mohammad Hashemi
Journal:  EXCLI J       Date:  2018-06-28       Impact factor: 4.068

Review 10.  Alternative Splicing by NOVA Factors: From Gene Expression to Cell Physiology and Pathology.

Authors:  Jacopo Meldolesi
Journal:  Int J Mol Sci       Date:  2020-05-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.